Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 10/20 | 0.52 |
| ▸ | OPRL1 | P41146 | 9/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341051 | 0.86 | OPRM1 (0.50) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6341426 | 0.86 | OPRM1 (0.50) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6341585 | 0.86 | OPRM1 (0.53) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6339137 | 0.85 | OPRM1 (0.49) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6340319 | 0.85 | OPRL1 (0.49) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6340823 | 0.85 | OPRM1 (0.50) | OPRM1OPRL1SIGMAR1KCNH2 | |
| Hydrochloric Acid SCHEMBL6345990 | 0.84 | OPRM1 (0.48) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6339115 | 0.84 | OPRM1 (0.57) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6339393 | 0.83 | OPRM1 (0.48) | OPRM1OPRL1SIGMAR1KCNH2ALDH1A1 | |
| SCHEMBL6347787 | 0.82 | OPRL1 (0.48) | OPRM1OPRL1SIGMAR1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6869960-B2 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. (US) | 2005-03-22 | — | — | US | claimed |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | ITO FUMITAKA (JP) | 2003-08-21 | — | — | US | claimed |
| US-6869960-B2 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | PFIZER INC. (US) | 2005-03-22 | — | — | US | disclosed |
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | ITO FUMITAKA (JP) | 2003-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158219-A1 | N-substituted spiropiperidine compounds as ligands for ORL-1 receptor | OGFRL1, OXER1, ORMDL3 | OPRM1 23/4885OPRL1 7/4885SIGMAR1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.